WHO ICTRP trial
HLA-haploidentical allogeneic stem cell transplantation for refractory…
JPRN-UMIN000011293 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000011293 |
|---|---|
| Public title | HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic malignancies (OCU13-3) |
| Scientific title | HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic malignancies (OCU13-3) - HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic malignancies (OCU13-3) |
| Primary sponsor | Osaka City University |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Acute myeloid leukemia(AML) Acute lymphoblastic leukemia (ALL) Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS) |
| Interventions | Fludarabine (15 mg/square meter of body surface area twice a day for 2 days and 30 mg/square meter once a day for 4 days), cytarabine (2 g/square meter twice a day for 2 days), Melphalan (100mg/ square meter per day for 1 day) is used as a… |
| Registration date | Jul 26, 2013 |
| Target size | 35 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: